Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 5/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.30 |
| ▸ | IDH1 | O75874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL730097 | 0.84 | HCRTR2 (0.33) | HCRTR2KDM4EHSD17B10TRPV3IDH1 | |
| SCHEMBL13604930 | 0.83 | OPRL1 (0.34) | OPRL1TRPV3 | |
| SCHEMBL10043094 | 0.83 | GPR119 (0.37) | OPRL1GPR119HCRTR2 | |
| SCHEMBL731637 | 0.82 | OPRL1 (0.40) | OPRL1GPR119 | |
| SCHEMBL729408 | 0.80 | — | — | |
| SCHEMBL1253846 | 0.80 | OPRL1 (0.40) | OPRL1GPR119 | |
| SCHEMBL729375 | 0.80 | GPR119 (0.37) | GPR119HCRTR2 | |
| SCHEMBL15061053 | 0.80 | GPR119 (0.35) | GPR119HCRTR2 | |
| SCHEMBL12918525 | 0.79 | ESR2 (0.36) | OPRL1TRPV3 | |
| SCHEMBL730045 | 0.79 | GPR119 (0.35) | GPR119HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2279990-B1 | LIQUID CRYSTALLINE TETRACYCLIC COMPOUND HAVING FLUORINE ATOM, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORP (JP) | 2016-10-26 | — | — | EP | disclosed |
| US-8137583-B2 | Liquid crystal four-ring compound having fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8137583-B2 | Liquid crystal four-ring compound having fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8137583-B2 | Liquid crystal four-ring compound having fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20110079753-A1 | LIQUID CRYSTAL FOUR-RING COMPOUND HAVING FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION | 2011-04-07 | — | — | US | disclosed |
| US-20110079753-A1 | LIQUID CRYSTAL FOUR-RING COMPOUND HAVING FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION | 2011-04-07 | — | — | US | disclosed |
| US-20110079753-A1 | LIQUID CRYSTAL FOUR-RING COMPOUND HAVING FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION | 2011-04-07 | — | — | US | disclosed |
| EP-2279990-A1 | LIQUID CRYSTALLINE TETRACYCLIC COMPOUND HAVING FLUORINE ATOM, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2011-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110079753-A1 | LIQUID CRYSTAL FOUR-RING COMPOUND HAVING FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | ROCK1, ROCK2, LEF1 | OPRL1 3448/4885GPR119 2229/4885HCRTR2 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.